Trial Profile

A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2023 Results assessing long-term hepatic safety of lomitapide from phase III clinical studies and extension study: NCT00730236, NCT00943306 and NCT02135705 published in the Liver International
18 Jul 2017 Results of an open-label extension study assessing additional long-term efficacy and safety of lomitapide along with results of an exploratory post hoc analysis assessing the potential metabolic consequences of hepatic fat accumulation, published in the Circulation Journal as a research letter.
18 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com